Insmed Inc.
Insmed Announces Additional Positive Data from ASPEN Study to be Presented at WBC
Summary
Insmed Incorporated announced on July 3, 2024, that additional positive results from its ASPEN study, assessing the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis, will be presented at the 7th World Bronchiectasis Conference on July 4, 2024. The study found that brensocatib significantly reduced the annualized rate of pulmonary exacerbations and improved lung function as measured by FEV1 and FVC. The data also indicated potential improvements in patient quality of life. Insmed plans to file a New Drug Application for brensocatib in the fourth quarter of 2024, with potential launches in the U.S., Europe, and Japan pending regulatory approvals.
Profitelligence Alerts
Get alerts for INSM
Be first to know when Insmed Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Insmed Inc.
Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.
Official SEC Documents
Advertisement